GP10（CJC-1295 Without DAC 5mg + Ipamorelin 5mg）
CJC-1295 (No DAC) 5mg + Ipamorelin 5mg blend is a research-grade, lyophilized peptide combination designed to synergistically stimulate growth hormone (GH) secretion via dual activation of the GHRH receptor and GHS-R1a (ghrelin receptor). Formulated for preclinical studies in anti-aging, muscle regeneration, metabolic modulation, and tissue recovery, this 1:1 ratio delivers a physiologically patterned GH pulse—mimicking the body’s natural GH release pattern to elevate IGF-1 levels.
| 10mg*10vials | $95 |
Product Information
What is GP10? (Full Composition & Profile)
CJC-1295 Without DAC (5mg)
- Full Name: Modified GRF (1–29), CJC-1295 No DAC (Drug Affinity Complex)
- Class: GHRH (growth hormone-releasing hormone) analog
- Structure: 29-amino-acid peptide with 4 stabilizing modifications; no long-chain DAC extension
- Half-life: ~30 minutes – 2 hours (short-acting, pulse-restricted)
- Purity: ≥99% (HPLC validated)
Ipamorelin (IPA, 5mg)
- Class: Selective GHS (growth hormone secretagogue), pentapeptide
- Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
- Half-life: ~1–2 hours
- Key Selectivity: Does not elevate cortisol, prolactin, or ACTH (unlike GHRP-2/GHRP-6)
GP10 Blend Specifications
- Total: 10mg lyophilized powder (5mg + 5mg 1:1 ratio)
- Form: Sterile lyophilized cake; reconstitute with bacteriostatic water (BAC) or 0.9% saline
- Storage:
- Unreconstituted: −20°C, dry, dark (stable ≥2 years)
- Reconstituted: 2–8°C, use within 30 days; avoid freeze–thaw
Target Research Populations & Applications
GP10 is optimized for preclinical models studying:
- Age-related GH/IGF-1 decline (sarcopenia, frailty, impaired recovery)
- Muscle & soft-tissue repair: tendon/ligament injury, post-surgical recovery, muscle wasting
- Metabolic research: body composition (fat loss + lean mass retention), insulin sensitivity
- Anti-aging & regenerative biology: skin aging, wound healing, neuroprotection
- Endocrine pharmacology: GH pulse dynamics, pituitary receptor crosstalk
Mechanism of Action (Dual-Path Synergy)
CJC-1295 No DAC (GHRH Pathway)
- Binds pituitary GHRH receptors → activates cAMP/PKA → GH vesicle exocytosis
- Increases amplitude of natural GH pulses (sharp, physiological peaks)
- Avoids receptor desensitization (short half-life preserves pulsatility)
Ipamorelin (GHS-R1a Pathway)
- Activates pituitary ghrelin (GHS-R1a) receptors → Ca²⁺ influx → GH secretion
- Inhibits somatostatin (the endogenous GH “brake”) → increases frequency of GH pulses
- Ultra-selective: no HPA-axis activation or prolactin rise
GP10 Synergistic Effect (1+1 > 2)
- Amplitude (CJC) + Frequency (IPA) → sustained, physiological GH/IGF-1 elevation (2–5× baseline)
- No hormonal interference: clean GH/IGF-1 signal without cortisol/prolactin side effects
- Downstream effects: angiogenesis, collagen synthesis, cell proliferation, anti-inflammation, anti-apoptosis
